Reference priceEUR €577.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Bavencio |
|---|---|
| Manufacturer | MSD Merck Sharp & Dohme AG |
| Prescription required | Yes |
Bavencio 20mg/ml solution 1flacon x 10ml(Avelumab)
avelumab
Description
Bavencio 20mg/ml solution 1flacon x 10ml(Avelumab) is a medicine catalog record in the MediPriceHub database. Active ingredient: avelumab. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: MSD Merck Sharp & Dohme AG. Therapeutic category: Medicine Library > Oncology Medicines > Urothelial Carcinoma. Pack information: 20 /, 1 x 10. Origin country or market: France. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for: Merkel Cell Carcinoma (MCC) Urothelial Carcinoma (UC) Renal Cell Carcinoma (RCC) Adults and pediatric patients 12 years and older with metastatic MCC. Maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy. Patients with locally advanced or metastatic UC who: Have disease progression during or following platinum-containing chemotherapy. Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Have disease progression during or following platinum-containing chemotherapy. Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. First-line treatment, in combination with axitinib, of patients with advanced RCC.How to Use
Use avelumab under the supervision of a qualified healthcare professional. Use it only according to the approved label and the instructions of a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: avelumab. Pack size: 20 /, 1 x 10. Pack unit: bottle. Manufacturer: MSD Merck Sharp & Dohme AG. Origin country: France. Source category: Medicine Library > Oncology Medicines > Urothelial Carcinoma. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.Esta información es solo orientativa. Consulta a un profesional sanitario antes de usar cualquier medicamento.